Charles River Laboratories International (CRL) Debt to Equity (2009 - 2025)

Charles River Laboratories International (CRL) has reported Debt to Equity for 17 consecutive years, with $0.67 the latest figure, recorded in Q4 2025.

• In Q4 2025, Debt to Equity rose 4.14% year-over-year to $0.67; the TTM figure through Dec 2025 stood at $0.67 (up 4.14% YoY), while the FY2025 annual figure was $0.67, up 4.14% from the prior year.
• Debt to Equity came in at $0.67 for Q4 2025 at Charles River Laboratories International, up from $0.64 in the prior quarter.
• The five-year high for Debt to Equity was $1.19 in Q3 2021, with the low at $0.61 in Q3 2024.
• Average Debt to Equity over 5 years is $0.86, with a median of $0.8 recorded in 2025.
• Across the five-year window, Debt to Equity rose 12.36% in 2021 and tumbled 31.98% in 2023, its largest moves.
• Year by year, Debt to Equity stood at $1.05 in 2021, then declined by 13.51% to $0.91 in 2022, then decreased by 19.09% to $0.73 in 2023, then retreated by 11.93% to $0.65 in 2024, then grew by 4.14% to $0.67 in 2025.
• According to Business Quant data, Debt to Equity over the past three periods registered $0.67, $0.64, and $0.69 for Q4 2025, Q3 2025, and Q2 2025 respectively.